Home
Elise Aasebø's picture

Elise Aasebø

Guest Researcher
  • E-mailelise.aasebo@uib.no
  • Visitor Address
    BB-bygget
    Jonas Lies vei 91
    Room 
    6C131cA
  • Postal Address
    Postboks 7804
    5020 Bergen

Uses mass spectrometry-based quantitative proteomics to analyze the proteome in acute myeloid leukemia (AML) patient cells, aiming to unravel more of the complex biological processes behind AML and to find prognostic biomarkers which can guide therapeutic decisions.

Other research interests are cell-cell communication in the AML microenviroment and proteomic method optimization.

Academic article
  • Show author(s) (2017). Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia. Journal of Proteomics. 32-41.
  • Show author(s) (2016). Systemic Analysis of Regulated Functional Networks. Methods in molecular biology. 287-310.
  • Show author(s) (2016). Reliable FASP-based procedures for optimal quantitative proteomic and phosphoproteomic analysis on samples from acute myeloid leukemia patients. Biological Procedures Online. 1-10.
  • Show author(s) (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. Proteomics. 1154-1165.
  • Show author(s) (2014). Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 1971-1976.
  • Show author(s) (2014). Effects of blood contamination and the rostro-caudal gradient on the human cerebrospinal fluid proteome. PLOS ONE.
Academic literature review
  • Show author(s) (2019). An overview on G protein-coupled receptor-induced signal transduction in acute myeloid leukemia. Current Medicinal Chemistry. 5293-5316.
  • Show author(s) (2018). Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia. Expert Review of Hematology. 13-24.
  • Show author(s) (2017). Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opinion on Drug Discovery. 1053-1065.
  • Show author(s) (2016). Selecting Sample Preparation Workflows for Mass Spectrometry-Based Proteomic and Phosphoproteomic Analysis of Patient Samples with Acute Myeloid Leukemia . Proteomes.

More information in national current research information system (CRIStin)

Acute myeloid leukemia research